This company is no longer active
0KB2 Stock Overview
A clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Humanigen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.013 |
| 52 Week High | US$0.02 |
| 52 Week Low | US$0.01 |
| Beta | -0.97 |
| 1 Month Change | 0% |
| 3 Month Change | 1.52% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0KB2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.3% | 0.3% |
| 1Y | n/a | -11.7% | 8.4% |
Return vs Industry: Insufficient data to determine how 0KB2 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 0KB2 performed against the German Market.
Price Volatility
| 0KB2 volatility | |
|---|---|
| 0KB2 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0KB2 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0KB2's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 6 | Cameron Durrant | www.humanigen.com |
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis.
Humanigen, Inc. Fundamentals Summary
| 0KB2 fundamental statistics | |
|---|---|
| Market cap | €549.02k |
| Earnings (TTM) | -€49.46m |
| Revenue (TTM) | €1.57m |
0.4x
P/S Ratio0.0x
P/E RatioIs 0KB2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0KB2 income statement (TTM) | |
|---|---|
| Revenue | US$1.70m |
| Cost of Revenue | US$38.73m |
| Gross Profit | -US$37.03m |
| Other Expenses | US$16.61m |
| Earnings | -US$53.63m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.45 |
| Gross Margin | -2,179.40% |
| Net Profit Margin | -3,156.80% |
| Debt/Equity Ratio | 0% |
How did 0KB2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/12/05 01:15 |
| End of Day Share Price | 2023/09/07 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Humanigen, Inc. is covered by 13 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Cosme Ordoñez | B. Riley Wealth |
| Olga Smolentseva | Bryan Garnier & Co |
| Louise Chen | Cantor Fitzgerald & Co. |